The Limited Times

Now you can see non-English news...

In order to fight the fourth wave: the FDA has approved a third dose of Modern | Israel today

2021-10-14T20:09:14.340Z


The Food and Drug Administration has recommended that the US administration provide an impetus to the elderly population against the spread of the corona delta virus • Pfizer's booster has been approved in the past • So far more than 700,000 people have died from the plague in the US


The expert panel advising the US Food and Drug Administration (FDA) this evening (Thursday) unanimously voted to recommend a modern company's corona vaccine for an booster dose for the elderly population and at risk of a serious illness, Reuters reported.  

On Friday, another session of the advisory body to the Food and Drug Administration is expected to take place and discuss the recommendation of the Johnson & Johnson vaccine as a booster dose for the elderly and at-risk population in the United States.

If the Food and Drug Administration accepts the recommendation, as is usually the case, the American Center for Contagious Disease Control (CDC) will publish a specific label for the third modern-day vaccine.

The center's consultants are expected to meet and discuss the issue as early as next week.

Moderna submitted the request along with a proposal to give a third booster dose at half the amount given in the first two vaccine shots (40 micrograms), which is still more than the booster dose of Pfizer, which underwent the approval procedure for administration to the elderly population and at a risk of 30 micrograms.

Professional figures in the United States are under pressure from the political system to allow impulses to be given to curb the spread of the Delta variant in the country, after more than 700,000 people died in the United States as a result of the corona plague.

Source: israelhayom

All news articles on 2021-10-14

You may like

Trends 24h

News/Politics 2024-04-18T09:29:37.790Z
News/Politics 2024-04-18T11:17:37.535Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.